Adis launches new open access pharmacoeconomics journal

August 02, 2016

Adis, a leading global provider of drug information, is launching a new open access pharmacoeconomics journal, which will be added to their portfolio in 2017. Called PharmacoEconomics - Open, the new journal will focus on cost and health outcomes associated with drugs, devices and other healthcare interventions. PharmacoEconomics - Open has the same co-editors as Adis's flagship subscription journal in the field, PharmacoEconomics. With 30 years of professional publishing experience between them, the co-editors will ensure that this new journal becomes an essential source of information.

Co-Editor Christopher Carswell at Adis says, "I am delighted to be part of the editorial team of PharmacoEconomics - Open. There is an ever-increasing need to provide credible open access journals to help researchers disseminate their work. PharmacoEconomics - Open provides such a venue for the health economics and outcomes research community. It will allow researchers to maximize the reach of their work not only within the research community but also amongst the most important stakeholder of all -- the patient."

Co-Editor Timothy Wrightson, also at Adis, adds, "We are excited to be providing this new publication which offers much-needed economic analyses and health outcomes research. This continues to be a rapidly growing field and is increasingly important as health budgets struggle to keep pace with medical innovations and population healthcare needs. Decision makers need access to these studies to inform optimal healthcare policy and practice."

The new journal will be published under the AdisOpen program meaning that it will appear online only and will be entirely open access. This will make it accessible to readers globally without the need for a subscription. All articles published in the journal will undergo rigorous peer review to ensure that they meet the high standards expected from Adis.
-end-
Adis has more than 40 years' experience in publishing, with a portfolio of more than 30 medical journals and newsletters. As part of Springer Nature, they are able to offer many benefits to authors including efficient article submission, tracking and review, expedited publication timelines, and high visibility through Springer Nature's proprietary content platforms. Visit http://www.springer.com/gp/adis

Springer is part of Springer Nature, a leading global research, educational and professional publisher, home to an array of respected and trusted brands providing quality content through a range of innovative products and services. Springer Nature is the world's largest academic book publisher, publisher of the world's most influential journals and a pioneer in the field of open research. The company numbers almost 13,000 staff in over 50 countries. Springer Nature was formed in 2015 through the merger of Nature Publishing Group, Palgrave Macmillan, Macmillan Education and Springer Science+Business Media. Visit http://www.springernature.com and follow @SpringerNature.

Springer

Related Drug Information Articles from Brightsurf:

Potent drug supply drop, not domestic drug policies, likely behind 2018 OD death downturn
The slight decline in drug overdose deaths in 2018 coincides with Chinese regulations on the powerful opioid carfentanil, rather than the result of domestic U.S. efforts to curb the epidemic, a new analysis reveals.

Charcoal-based drug delivery system improves efficacy of common herpes drug
A study led by researchers from the University of Illinois at Chicago has found that combining acyclovir -- a commonly prescribed topical herpes medication -- with particles of activated carbon improves efficacy of the drug.

Bringing information into the cell
Researchers at the Paul Scherrer Institute PSI have elucidated an important part of a signal pathway that transmits information through the cell membrane into the interior of a cell.

Better safeguards for sensitive information
Despite being the most advanced quantum technology, secure encryption of information units based on a method called quantum key distribution (QKD) is currently limited by the channel's capacity to send or share secret bits.

Arming drug hunters, chemists design new reaction for drug discovery
Colorado State University organic chemists have forged a powerful new tool for drug hunters -- a simple, elegantly designed chemical reaction that could fling open an underexplored wing of biologically relevant chemistry.

New drug candidates reverse drug resistance in multiple myeloma in preclinical models
A new strategy to enhance the activity of proteasome inhibitors (PIs), which are standard-of-care agents in the treatment of multiple myeloma (MM), was reported by researchers at the Medical University of South Carolina in the journal Leukemia.

Discrepancies found in prescription drug labeling pregnancy information across four countries
A study comparing the evidence and recommendation levels of pregnancy information in new prescription drug labeling found significant discrepancies in labeling information among the United States, the United Kingdom, Japan, and Korea.

Deep learning predicts drug-drug and drug-food interactions
A Korean research team from KAIST developed a computational framework, DeepDDI, that accurately predicts and generates 86 types of drug-drug and drug-food interactions as outputs of human-readable sentences, which allows in-depth understanding of the drug-drug and drug-food interactions.

AACR: How do melanoma cells survive drug treatment long enough to acquire drug resistance?
'What we find is that dabrafenib, even at high doses, does not fully turn off the MAPK pathway, thereby enabling eventual escape from drug,' says Sabrina Spencer, Ph.D.

Drug combined with care program better at reducing Alzheimer's symptoms than drug alone
Combining a specific care management program with a commonly-prescribed drug for Alzheimer's, memantine, multiplies the medication's ability to improve daily function by about 7.5 times, stalling some of the disease's most damaging effects, according to new research from NYU Langone Medical Center.

Read More: Drug Information News and Drug Information Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.